To Our Shareholders
and Investors

• December 04, 2025

  R & D
  CAP-1002：Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase III HOPE-3 Study in Duchenne Muscular Dystrophy
• November 20, 2025

  R & D
  Anti-Cancer Agent/Humanized Anti-CD20 Monoclonal Antibody Gazyva,Now Available for Use in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
• November 14, 2025

  Management & Finance
  Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2025
• October 30, 2025

  R & D
  Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults

Upcoming Events

• November 14, 2025
  IR Meeting(Q2/FY2025)
• November 14, 2025
  FY2025 2nd Qtr results announcement
• August 07, 2025
  Conference Call(Q1/FY2025)
• August 07, 2025
  FY2025 1st Qtr results announcement
• May 08, 2025
  IR Meeting (Q4/FY2024) PDF1.0 MB